INTRODUCTION {#s1}
============

Every year around one million new cases of gastric cancer are diagnosed globally. In 2012, 723,000 people died from gastric cancer, ranking it the 4^th^ most common cancer-related cause of death. Complete surgical resection together with perioperative chemotherapy represents the standard of care for curative treatment of patients with gastric cancer \[[@R1]-[@R3]\]. However, even after multimodal therapy up to 40% of the patients experience disease recurrence and up to 30% die within 12 months \[[@R4]\].

Peritoneal dissemination is a common cause of failure after curative treatment for gastric cancer. Peritoneal recurrence occurs in 17% of patients undergoing resection with curative intent and is associated with a dismal survival \[[@R5], [@R6]\]. Due to the frequent occurrence and the strong prognostic relevance of peritoneal metastases, detection of free intraperitoneal tumor cells (FITC) has been suggested as a prognostic and predictive biomarker in gastric cancer patients \[[@R7], [@R8]\]. Detection of FITC may help to recognize those patients considered for curative therapy who are at high-risk for early tumor relapse and might benefit from intensified treatments such as hyperthermic intraperitoneal chemotherapy (HIPEC) \[[@R9]\]. Numerous studies have so far been conducted on the prognostic and predictive value of FITC in gastric cancer. Although FITC are found in 6-49% of gastric cancer patients considered for curative surgery \[[@R10]-[@R13]\], it\'s predictive and prognostic value has remained unclear due to inconsistent detection techniques and results of the individual studies. This clinical uncertainty is reflected by inconsistent recommendations made by different guidelines on the use of FITC in the management of gastric cancer \[[@R1]-[@R3], [@R14]\].

To clarify the role of intraperitoneal lavage cytology as a prognostic biomarker in gastric cancer, we performed a systematic review with meta-analyses of studies on the prognostic significance of FITC detection in peritoneal lavage samples of patients with gastric cancer considered for curative therapy.

RESULTS {#s2}
=======

Baseline study characteristics {#s2_1}
------------------------------

In total, we included 64 studies \[[@R10]-[@R13], [@R15]-[@R68]\] with a cumulative sample size of 12, 883 patients (Figure [1](#F1){ref-type="fig"}). These studies had a median sample size of 134 (52 - 1297) patients and were published between 1978 and 2014 (Table [1](#T1){ref-type="table"}). The included studies were conducted in Western institutions in 19% and in Asian institutions in 81%. Patients with stage IV disease were enrolled in 30 (47%) studies. The median follow up across all studies was 35 (18 - 82) months. FITC were detected by cytology in 43 (67%) studies (38 studies used Papanicolaou staining, 5 studies used H&E staining), by immunocytochemistry (ICC) in 5 (8%) studies and by RT-PCR in 29 (45%) studies (Table [2](#T2){ref-type="table"}). The majority of studies used Carcinoembryonic antigen (CEA) for molecular tumor cell detection. In 22 studies CEA expression was analyzed and in seven studies CK20 expression was analyzed. Further markers included CK19, CD44, Caspase 9, MINT, MAGE, MMP 7, CA125, TGFβ, RegIV, FABP1, Muc2, IL-17 and CDH1. The detection rate of FITC across the included studies varied markedly (median: 23%; range 6% - 58%) and showed a strong association with patients' stage of disease and in particular the inclusion of patients with overt peritoneal metastases. FITC were detected prior to resection in 62 (97%) studies and pre- as well as postoperativelv in 2 (3%) studies. OS, DSS, DFS and PRFS was reported in 51 (80%), 7 (11%), 11 (17%) and 21 (33%) studies, respectively. Hazard ratios for multivariate analysis could be extracted in 21 studies (ten that performed cytology, eight that performed RT-PCR and three that performed both). Fifteen studies were graded with a low risk of bias ([Appendix 1](#SD1){ref-type="supplementary-material"}). Funnel plot analyses did not indicate significant publication bias for the analyzed outcomes ([Appendix 2](#SD1){ref-type="supplementary-material"}).

![Flow diagram showing the selection process for relevant studies](oncotarget-06-35564-g001){#F1}

###### Baseline characteristics of included studies

  First author      Year of publication   Study type   Period of enrollment   Country of origin   Sample size   Age         Female/Male (%)   Stage          M1    FITC positive (%)   Neo. Chem. (%)   Adj. Chem. (%)   Pall. Chem.   Chemotherapy Regimen
  ----------------- --------------------- ------------ ---------------------- ------------------- ------------- ----------- ----------------- -------------- ----- ------------------- ---------------- ---------------- ------------- ------------------------------------
  Badgwell, B       2008                  RSCS         1995 - 2005            USA                 379           61          35%/65%           UICC II-IV     22%   15%                 6%               NA               26%           NA
  Bando             1999                  RSCS         1975 - 1997            Japan               1297          NA          NA                UICC II-IV     23%   24%                 NA               NA               NA            NA
  Benevolo          1998                  RSCS         1989 - 1996            Italy               80            61          41%/59%           UICC I-III     0%    15%                 0%               50%              NA            NA
  Bentrem           2005                  RSCS         1993 - 2002            USA                 371           57          44%/56%           UICC I-III     0%    6%                  NA               NA               NA            NA
  Boku              1990                  RSCS         1984 - 1987            Japan               93            NA          NA                T4, P0         0%    20%                 NA               NA               NA            NA
  Bonenkamp         1996                  RSCS         1989 - 1993            Netherland          457           30% \>70    41%/59%           UICC I-III     0%    7%                  NA               NA               NA            NA
  Chang Qing        2011                  RSCS         2006 - 2007            China               53            54          57%/43%           UICC I-IV      NA    58%                 0%               NA               NA            NA
  Chuwa,            2005                  PSCS         1998 - 2002            Singapore           142           67          36%/64%           UICC I-IV      25%   25%                 0%               NA               NA            NA
  Euanorasetr, C.   2007                  RSCS         1997 - 2005            Thailand            97            59          50%/50%           UICC I-III     0%    23%                 NA               NA               NA            NA
  Fujimoto          2002                  RSCS         1981-1997              Japan               96            60          32%/68%           UICC I-III     0%    33%                 0%               13%              NA            5FU; MMC; OK-432
  Fujiwara          2014                  PSCS         2007 - 2009            Japan               137           66          32%/68%           UICC I-IV      8%    CY 20%; PCR 61%     0%               71%              NA            S1
  Fukagawa          2010                  RSCS         1992 - 1998            Japan               573           NA          NA                UICC II-IV     18%   28%                 0%               58%              NA            NA
  Fukuda, Y         2011                  RSCS         2001 - 2009            Japan               71            69          25%/75%           T4a + b M0     0%    38%                 0%               71%              NA            5-FU; Paclitaxel
  Han               2014                  RSCS         2008 - 2009            China               92            74% \<60    41%/59%           UICC I-IV      8%    49%                 0%               NA               NA            NA
  Hao, Y. X.        2010                  PSCS         2004 - 2009            China               164           53          59%/41 %          UICC I-III     0%    55%                 0%               NA               NA            NA
  Hara              2007                  RSCS         2001 - 2003            Japan               76            63          67%/33%           UICC I-III     0%    15%                 0%               NA               NA            NA
  Hayes             1999                  RSCS         1992 - 1994            UK                  85            69          22%/78%           UICC I-IV      24%   19%                 NA               NA               NA            NA
  Horikawa          2011                  RSCS         2000 - 2006            Japan               147           66          66%/34%           UICC II-III    0%    33%                 NA               NA               NA            NA
  Iida              2013                  RSCS         2003 - 2006            Japan               79            35% \>65J   27%/73%           UICC I-III     0%    44%                 0%               NA               NA            NA
  Ikeguchi          1994                  RSCS         1976 - 1989            Japan               229           60          39%/61%           UICC II-IV     23%   33%                 0%               100%             NA            NA
  Ishii             2004                  RSCS         1999 - 2002            Japan               60            NA          NA                UICC I-IV      15%   23%                 0%               NA               NA            NA
  Ito               2005                  PSCS         2000-2002              Japan               283           NA          NA                UICC I-III     0%    23%                 0%               21%              NA            NA
  Jeon              2010                  RSCS         2002 - 2003            Korea               84            44% \>65    38%/62%           UICC I-III     0%    13%                 NA               NA               NA            NA
  Jeon              2014                  RSCS         2009 - 2010            Korea               117           45% \>65    42%/58%           UICC I-III     0%    33%                 0%               NA               NA            NA
  Jiang             2011                  RSCS         1997 - 2002            China               139           57          32%/68%           UICC I-IV      28%   27%                 0%               27%              22%           NA
  Kang              2014                  PSCS         2010 - 2010            Korea               75            41% \>65    33%/67%           UICC I-III     0%    9%                  NA               NA               NA            5FU
  Katsuragi         2007                  RSCS         NA                     Japan               117           NA          NA                UICCI-IV       11%   19%                 NA               NA               NA            NA
  Kodera            1998                  RSCS         NA                     Japan               148           NA          NA                UICC I-IV      17%   CY 16%; PCR 28%     0%               NA               NA            NA
  Kodera            1999                  PSCS         1995 - 1998            Japan               91            61          60%/40%           UICC II-III    0%    11%                 0%               26%              NA            NA
  Kodera            2006                  RSCS         1995 - 1999            Japan               274           60          NA                UICC I-IV      12%   38%                 0%               NA               NA            NA
  La Torre          2010                  PSCS         2003 - 52008           Italy               64                        NA                UICC I - III   0%    11%                 0%               42%              NA            NA
  Lee               2012                  RSCS         2001 - 2009            Korea               1072          55          33%/67%           UICC I-IV      14%   16%                 NA               69%              NA            NA
  Li                2005                  PSCS         1995 - 1997            China               64            59          34%/66%           UICC I-III     0%    23%                 0%               NA               NA            NA
  Li                2014                  RSCS         2007 - 2008            China               116           61          39%/67%           UICC I-III     0%    35%                 0%               61%              NA            NA
  Makino            2010                  RSCS         2002 - 2006            Japan               113           63          37%/63%           UICC II-IV     10%   31%                 0%               30%              NA            MMC + Cisplatin
  Manzoni           2006                  RSCS         1992 - 2002            Italy               168           65          37%/63%           UICC I-III     0%    14%                 0%               0%               NA            NA
  Miyagawa          2008                  RSCS         1999 - 2004            Japan               95            NA          32%/68%           UICC I-IV      16%   49%                 NA               NA               NA            NA
  Miyashiro         2005                  RSCS         1975 - 1994            Japan               320           61          39%/61%           UICC I-III     0%    8%                  NA               92%              NA            NA
  Nakajima          1978                  RSCS         1972 - 1976            Japan               196           NA          NA                UICC I-III     0%    16%                 0%               43%\*; 58%\*\*   NA            MMC + 5FU or Futraful + Cytarabine
  Nekarda           1999                  PSCS         1987 - 1990            Germany             118           59          33%/67%           UICC I-III     0%    20%                 0%               0                NA            NA
  Oyama             2004                  RSCS         1997 - 2001            Japan               163           64          32%/68%           UICC I-IV      14%   28%                 0%               17%\*; 93%\*\*   NA            5-FU +/− Cisplatin
  Ozer              2012                  RSCS         2000 - 2007            Turkey              255           60          35%/65%           UICC I-III     0%    14%                 NA               NA               NA            NA
  Ribeiro           2006                  PSCS         1993 - 2002            Brazil              201           61          36/64%            UICC I-III     0%    7%                  0%               0%               NA            NA
  Rosenberg         2006                  RSCS         1987 - 2001            Germany             346           64          37%63%            UICC I-III     0%    21%                 0%               NA               NA            NA
  Ryu               2008                  RSCS         2001 - 2006            Korea               424           60          36%/64%           UICC I-IV      22%   27%                 NA               NA               NA            NA
  Satoh             2012                  RSCS         NA                     Japan               61            NA          NA                UICC I-IV      26%   23%                 NA               NA               NA            NA
  Sugita            2003                  RSCS         1998 - 2002            Japan               114           NA          NA                UICC I-IV      10%   CY 7%; PCR 46%      0%               NA               NA            NA
  Suzuki            1999                  RSCS         1988 - 1996            Japan               347           NA          NA                UICC I-IV      4%    8%                  NA               8,4%             NA            NA
  Takata            2013                  RSCS         2009 - 2012            Japan               104           63% \>65J   46%/54%           UICC I-III     0%    15%                 19%              NA               NA            S1 + Cisplatin and/or Docetaxel
  Takebayashi       2014                  RSCS         2009 - 2012            Japan               102           68          42%/58%           UICC I-III     0%    56%                 NA               NA               NA            NA
  Tamura            2007                  RSCS         2000 - 2005            Japan               164           NA          35%/65%           UICC I-IV      9%    27%                 NA               NA               NA            NA
  Tamura            2014                  PSCS         2007 - 2009            Japan               124           66          30%/70%           UICC I-IV      10%   CY 20%; PCR 61%     0%               71%              NA            S1
  Tokuda            2003                  RSCS         1997 - 1999            Japan               131           NA          32%/68%           UICC I-III     0%    CY 4%; PCR 22%      NA               NA               NA            NA
  Ueno              2003                  RSCS         1998 - 2001            Japan               79            NA          33%/67%           UICC I-IV P0   5%    40%                 0%               0%\*; 100%\*\*   NA            NA
  Vogel             1999                  PSCS         1992 - 1995            Germany             75            65          34%/66%           UICC I-III     0%    42%                 NA               NA               NA            NA
  Wong              2012                  PSCS         2007 - 2009            USA                 118           NA          NA                UICC I-IV      0%    20%                 NA               NA               98% \*\*\*    NA
  Wu                1997                  RSCS         1990 - 1993            Taiwan              129           64          21%/79%           UICC II-III    0%    19%                 0%               NA               NA            MMC
  Yamamoto          2009                  RSCS         2000 - 2006            Japan               566           NA          34%/66%           UICC I-IV      20%   10%                 0%               98% \*\*\*       NA            S1 or S1 combination
  Yamamoto          2014                  RSCS         2006 - 2011            Japan               193           68.4        NA                UICC I-IV      21%   27%                 NA               21%              NA            S1
  Yamashita         2009                  RSCS         1990 - 2000            Japan               232           NA          31%/69%           UICC I-III     0%    34%                 NA               NA               NA            NA
  Yoneda            2014                  RSCS         2007 - 2008            Japan               52            68          33%/67%           UICC I-IV      23%   40%                 NA               NA               NA            NA
  Yonemura          2001                  RSCS         1993 - 1999            Japan               230           59          20%/80%           UICC I-III     0%    CY 19%; PCR 17%     NA               NA               NA            NA
  Yoshikhawa        2003                  RSCS         1987 - 1997            Japan               149           61          33%/67%           UICC II-III    0%    22%                 NA               NA               NA            NA
  Yu                2012                  RSCS         2008 - 2009            China               92            74% \<60    41%/59%           UICC I-IV      8%    49%                 0%               NA               NA            NA

Legend:

[Study type:]{.ul} Prospective cohort study (PSCS) and retrospective cohort study (RSCS)

[Age:]{.ul} Age includes median age. If median age was not available, mean age was used.

Stage: Included stages. All stages are calculated according to the official TNM classification of the "Union internationale contre le cancer" (UICC) \[[@R1]\]

[M1:]{.ul} Percentage of patients that had metastasized disease (M1)

[FITC positive:]{.ul} Percentage of patients that had free intraperitoneal tumor cells (FITC)

[Neo. Chem.:]{.ul} Percentage of patients that received neoadjuvant chemotherapy

[Adj. Chem.:]{.ul} Percentage of patients that received adjuvant chemotherapy

[Pall. Chem.:]{.ul} Percentage of patients that received palliative chemotherapy

[Chemotherapy Regimen:]{.ul} Includes all used chemotherapy regimens in the study; used abbreviations: Fluorouracil (5FU); Mitomycin C (MMC), Picibanil (OK-432), oral fluoropyrimidine S-1 (S-1)

1\. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. John Wiley & Sons; 2011. 209 p.

###### Design variables of included studies

  First author      Year of publication   A/W   CY   ICC   PCR   sample size   detection (rel. to surgery)   Sample quantity (ml)   collection site \*\*   detection target   LAD        Median follow up (median and range)   Outcomes reported   Multivariate
  ----------------- --------------------- ----- ---- ----- ----- ------------- ----------------------------- ---------------------- ---------------------- ------------------ ---------- ------------------------------------- ------------------- ---------------------------
  Badgwell          2008                  W     1                379           before surgery                1000                   PC                     CY                 NA         51                                    OS                  not significant
  Bando             1999                  A     1                1196          before surgery                200                    D, BO, LS              CY                 NA         NA                                    OS; PRFS            significant
  Benevolo          1998                  W     1    1           80            before surgery                50                     PC                     CY                 NA         \>24 (24 - NA)                        OS                  not performed
  Bentrem           2005                  W     1                              before surgery                100                    RS, LS, D              CY                 NA         36                                    OS                  significant
  Boku              1990                  A     1                93            before surgery                100                    D                      CY                 NA         NA                                    OS                  not performed
  Bonenkamp         1996                  W     1                535           before surgery                200                    D                      CY                 D1 - D2    NA                                    OS                  not performed
  Chang Qing        2011                  A                1     53            before surgery                NA                     Ascites                Caspase 9          NA         NA                                    OS                  not performed
  Chuwa             2005                  A     1                138           before surgery                200                    D, LS, LPG             CY                 D2         36 (13 to 59)                         OS; DFS             significant
  Euanorasetr, C.   2007                  A     1                97            before surgery                100                    D, BO, LS, RPG         CY                 D2         49 (3-119)                            OS                  significant
  Fujimoto          2002                  A     1                236           before surgery                200                    D, LS                  CY                 NA         \>36 (36 - NA)                        OS                  significant
  Fujiwara          2014                  A     1          1     137           before surgery                100                    PC                     CEA                D2         NA, probably 60                       OS; PRFS; DFS       significant
  Fukagawa          2010                  A     1    1           701           before surgery                100                    D                      CY                 NA         NA                                    OS                  not tested
  Fukuda            2011                  A     1                71            before surgery                NA                     NA                     CY                 D2         24 (1-89)                             OS                  significant
  Han               2014                  A                1     92            before surgery                200                    D, RS, LS, LPG         MINT2              NA         NA                                    DFS                 not significant
  Hao, Y. X.        2010                  A     1          1     164           before and after surgery      100                    D                      CEA                D2         38 (3--63)                            OS                  not tested
  Hara              2007                  A     1          1     76            before surgery                100                    D, LPG                 CEA CK 20          NA         22 (4.6 - 43)                         OS; DFS             significant
  Hayes             1999                  W     1                85            before surgery                100                    IT, LPG, D             CY                 D2         24                                    OS                  not tested
  Horikawa          2011                  A                1     147           before surgery                100                    D                      CD 44              NA         37 (7-68)                             OS; PRFS            significant
  Iida              2013                  A                1     79            before surgery                100                    D                      IL-17              NA         61                                    OS                  significant
  Ikeguchi          1994                  A     1                229           before surgery                50                     D                      CY                 NA         48 - 216                              OS                  not performed
  Ishii             2004                  A     1          1     60            before surgery                200                    D, LS                  CEA                NA         NA                                    OS; PRFS            not performed
  ito               2005                  A                1     86            before surgery                200                    D, LS                  CEA                NA         30 (21 - 50)                          OS; PRFS            significant
  Jeon              2010                  A                1     84            before surgery                200                    D                      MAGE               NA         60                                    OS                  significant
  Jeon              2014                  A                1     117           before surgery                100                    D                      MAGE/CEA           NA         36 (NA)                               DFS                 significant
  Jiang             2011                  A     1                139           before surgery                100                    D, LS                  CY                 NA         \>60                                  OS                  significant
  Kang              2014                  A     1                75            before surgery                400                    D, LS                  CY                 NA         30                                    OS; DFS             not performed
  Katsuragi         2007                  A                1     116           before surgery                100                    D, LS                  CEA; CK20          D2         32                                    OS                  significant
  Kodera            1998                  A                1     148           before surgery                100                    D                      CEA                D2         18 (5 - 32)                           OS; PRFS            not performed
  Kodera            1999                  A     1                91            before surgery                100                    D, LS                  CY                 D2/D3      25 (11 - 45)                          OS; PRFS            significant
  Kodera            2006                  A     1          1     274           before surgery                100                    D                      CEA                D2         82 (60 - 142)                         OS; PRFS            significant
  La Torre          2010                  W     1    1           64            before surgery                200                    D, LS, RS, LPG         CEA                D1 + CT    32 (12 - 56)                          OS                  significant
  **Lee**           2012                  A     1                **1072**      before surgery                200                    D, BO, LS, RS          CY                 D2         NA                                    OS                  significant
  Li                2005                  A     1                64            before surgery                50                     RS or D                CY                 NA         39 (9-74)                             OS                  only significant vor PRFS
  Li                2014                  A                1     116           before surgery                100                    D                      \*                 NA         36                                    PRFS                significant
  Makino            2010                  A     1                113           before surgery                500                    PC                     CY                 NA         29                                    OS                  not tested
  Manzoni           2006                  W     1                168           before surgery                200                    IT, D                  CY                 D2         64 (35 - 159                          OS; PRFS; DFS       not significant
  Myiagawa          2008                  A                1     95            before surgery                150                    D                      CY                 NA         \>24                                  OS                  significant
  Miyashiro         2005                  A     1                320           before surgery                150                    D                      CY                 NA         NA                                    OS                  not tested
  Nakajima          1978                  A     1                274           before surgery                200                    IT, RS, LS             CY                 NA         NA                                    OS                  not tested
  Nekarda           1999                  W     1    1           118           before surgery                500                    RS, LS                 CY                 D2         69 (41 - 84)                          OS                  significant
  Oyama             2004                  A                1     195           before surgery                100                    D                      CEA                D0 -- D2   26 (1,4 - 51)                         OS; PRFS; DFS       significant
  Ozer              2012                  W     1                255           before surgery                50                     LS                     CY                 D2-D3      18 (0,2 - 107)                        OS                  not significant
  Ribeiro           2006                  A     1                201           before surgery                100                    IT, LS, RS             CY                 D2         64 (55 - 73)                          OS                  significant
  Rosenberg         2006                  W     1    1           346           before surgery                500                    IT, LS                 Ber-EP4            NA         70 (24 - 204)                         OS                  significant
  Ryu               2008                  A     1                424           before surgery                200                    IT, D                  CY                 NA         24                                    OS; PRFS            significant
  Satoh             2012                  A                1     61            before surgery                NA                     NA                     CY                 NA         24 (1 - 33)                           PRFS                not performed
  Sugita            2003                  A     1          1     123           before surgery                100                    D, LS                  CEA/CK20           NA         NA                                    OS; PRFS; DFS       not performed
  Suzuki            1999                  A     1                347           before surgery                100                    D, LS                  CY                 NA         NA                                    OS                  significant
  Takata            2013                  A                1     104           before surgery                100                    D, LS                  CEA, CK-20         NA         18                                    DFS                 significant
  Takebayashi       2014                  A                1     102           before and after surgery      100                    PC                     CEA/CK20           NA         NA                                    PRFS                not performed
  Tamura            2007                  A                      164           before surgery                100                    D, LS                  CEA/CK20           NA         26 (18 - 65)                          OS; PRFS            significant
  Tamura            2014                  A                      137           before surgery                100                    D, LS                  CEA/CK20           D2         NA, probably 60                       PRFS                significant
  Tokuda            2003                  A     1                136           before surgery                200                    D, LS                  CY                 NA         27 (17 - 39)                          OS; PRFS            not performed
  Ueno              2003                  A     1          1     124           before surgery                100                    D, LS                  CEA                D2         30 (3 - 50)                           OS                  not performed
  Vogel             1999                  W     1                75            before surgery                100                    IT                     CY                 NA         45 (24.7 - 66)                        OS                  not performed
  Wong              2012                  W                1     118           before surgery                NA                     LS, RS, D              CEA                NA         35                                    OS                  not performed
  Wu                1997                  A     1                129           before surgery                200                    IT, LS                 CY                 D2         NA                                    OS                  not performed
  Yamamoto          2009                  A     1                566           before surgery                100                    D                      CY                 NA         30 (12 - 96)                          OS                  significant
  Yamamoto          2014                  A                1     193           before surgery                100                    D                      CEA/CA 72-4        D2         32                                    OS                  significant
  Yamashita         2009                  A     1                232           before surgery                NA                     NA                     CY                 NA         \>5y                                  OS                  significant
  Yoneda            2014                  A                1     52            before surgery                400                    PC                     CK19               NA         39 (6 - 51)                           OS; PRFS; DFS       not performed
  Yonemura          2001                  A     1          1     230           before surgery                1000                   PC                     CY                 NA         41 (4 - 74)                           OS; PRFS            significant
  Yoshikawa         2003                  A     1                149           before surgery                100                    D, LS                  CY                 D2/D3      NA                                    OS; PRFS            significant
  Yu                2012                  A                1     92            before surgery                200                    RS, LS, LPG            meth.CDH1          NA         NA                                    OS                  significant

Legend:

[A/W:]{.ul} Study population originating from asian (A) or western (W) countries

[CY/ICC/PCR:]{.ul} Shows which detection method was used to detect free intraperitoneal cells (FITC): cytology (CY), Immunocytochemistry (ICC) or quantitative real time polymerase chain reaction (PCR). 1 means the paper includes results using the mentioned detection method.

[Collection site:]{.ul} BO = bursa omentalis; D = douglas pouch; LS = left subphrenic space, RS = right subphrenic space; LPG = left paracolic gutter; RPG = right paracolic gutter; PC = peritoneal cavity (not specified)

[Detection target:]{.ul} only cytology (CY), Carcinoembryonic antigen (CEA), MINT2 gene (MINT2), cytokeratin (CK) 20, melanoma associated antigen (MAGE), Cluster of Differentiation (CD)-44, Interleukin (IL)-17, Ber-EP4 antibody (Ber-EP4), Carbohydrate Antigen (CA) 72-4, CK 19, methylated Cadherin-1 (CDH1), Matrix-Metalloproteinase (MMP)-7, Transforming growth factor (TGF)-b, \* = CEA, MMP 7, CK 20, CA 125, TGF b

[Lymphadenectomy (LAD):]{.ul} information not available (NA), D1, D2, coeliac trunc (CT)

[Outcomes reported:]{.ul} Overall survival (OS), disease free survival (DFS), peritoneal recurrence free survival (PRFS)

Prognostic value of FITC detection {#s2_2}
----------------------------------

Some 51 studies with a cumulative sample size of 11, 005 patients reported on OS.^10-13,\ 23-32,\ 34,\ 36,\ 38-43,\ 46-49,\ 51-60,\ 63-65,\ 67-7^ The pooled analyses of the results from these studies showed a strong prognostic value of FITC detection (HR 3.27, 95% CI 2.82 - 3.78; *n* = 51; I² = 74%) (Figure [2](#F2){ref-type="fig"}). This result could be verified in the 35 studies with curatively resected patients and a cumulative sample size of 5908 (3.51; 3.01 - 4.08; *n* = 35; I^2^ = 48%) (Table [3](#T3){ref-type="table"}) \[[@R10]-[@R13], [@R16]-[@R19], [@R22], [@R24], [@R25], [@R30]-[@R35], [@R37], [@R41], [@R44]-[@R49], [@R51], [@R56], [@R59], [@R60], [@R62], [@R65], [@R66], [@R68], [@R69]\]. Sensitivity analyses failed to identify a single study as a reason for the observed statistical heterogeneity. Meta-analysis of the results from 17 studies with multivariate analyses confirmed the prognostic association of FITC detection with reduced heterogeneity (2.45; 2.04 - 2.94; *n* = 17; I² = 39%) \[[@R11], [@R12], [@R21], [@R23], [@R25], [@R32], [@R33], [@R38], [@R40], [@R48], [@R52], [@R54], [@R62], [@R63], [@R65], [@R66], [@R68]\]. Furthermore, we found significant associations of FITC detection and long-term outcome in the pooled analyses on DFS (3.61; 2.63 - 4.96; *n* = 11; I² = 26%)\[[@R21], [@R23], [@R27], [@R34], [@R44], [@R48], [@R53], [@R64], [@R70], [@R71]\] and PRFS (4.15, 3.10 - 5.57; *n* = 14; I² = 30%) (Table [4](#T4){ref-type="table"}) \[[@R12], [@R23], [@R31], [@R38], [@R42], [@R44], [@R55], [@R56], [@R64]-[@R66], [@R72], [@R73]\].

![Forest plot for the prognostic value of FITC in patients with gastric cancer (Overall survival)](oncotarget-06-35564-g002){#F2}

###### Subgroup analyses for overall survival in FITC positive patients and curatively resected FITC positive patients

                                 Overall Survival   Overall Survival (Curative)                                                             
  ------------------------------ ------------------ ----------------------------- ----- --------- ---- ------ ------------- ----- --------- ----
  **Total:**                     3.27               2.82 - 3.78                   74%   0.00001   51   3.51   3.01 - 4.08   48%   0.00001   35
  **Multivariate:**              2.45               2.04 - 2.94                   39%   0.00001   17   3.37   2.04 - 5.57   65%   0.00001   8
  **Detection Method:**                                                                                                                     
  *CY*                           3.03               2.55 - 3.61                   78%   0.00001   35   3.19   2.75 - 3.69   38%   0.00001   25
  *PCR*                          3.64               2.93 - 4.53                   49%   0.00001   19   5.07   3.50 - 7.36   53%   0.00001   13
  **Stage of disease**                                                                                                                      
  *Advanced stage of disease*    2.88               2.47 - 3.36                   0%    0.00001   19   2.52   2.10 - 3.02   24%   0.00001   12
  *All stages*                   3.58               3.07 - 4.17                   45%   0.00001   34   3.23   2,98 - 3.50   41%   0.00001   27
  **Date of publication**                                                                                                                   
  *up to and including 2005*     3.49               2.68 - 4.56                   80%   0.00001   23   3.61   2.98 - 4.37   45%   0.00001   21
  *after 2005*                   3.13               2.66 - 3.68                   64%   0.00001   28   3.39   2.60 - 4.40   54%   0.00001   14
  **Study population**                                                                                                                      
  *Asian*                        3.31               2.77 - 3.95                   78%   0.00001   38   3.64   3.04 - 4.36   43%   0.00001   24
  *Western*                      3.17               2.50 - 4.01                   48%   0.00001   13   2.9    2.16 - 3.90   53%   0.00001   9
  **Size of study population**                                                                                                              
  *\<median*                     3.62               2.99 - 4.39                   34%   0.00001   26   3.77   2.80 - 5.09   51%   0.00001   17
  *\>median*                     2.98               2.45 - 3.62                   84%   0.00001   25   3.25   2.74 - 3.84   43%   0.00001   16
  **Risk of bias**                                                                                                                          
  *high*                         3.08               2.62 - 3.62                   74%   0.00001   39   3.35   2.85 - 3.95   42%   0.00001   26
  *low*                          3.96               2.92 - 5.38                   63%   0.00001   12   4.27   2.89 - 6.33   62%   0.00001   9
  **Lavage fluid**                                                                                                                          
  *\>150ml*                      3.38               2.47 - 4.27                   80%   0.00001   23   3.7    2.93 - 4.68   49%   0.00001   15
  *\<150ml*                      3.36               2.75 - 4.10                   65%   0.00001   25   3.47   2.78 - 4.32   52%   0.00001   18
  **FITC positive (%)**                                                                                                                     
  *\>median*                     3.31               2.61 - 4.19                   81%   0.00001   28   3.36   2.67 - 4.21   56%   0.00001   20
  *\<=median*                    3.15               2.72 - 3.64                   46%   0.00001   24   3.73   3.07 - 4.53   31%   0.00001   15
  **Chemotherapy**                                                                                                                          
  *\>25% adj. Chemo*             3.56               3.15 - 4.01                   0%    0.00001   9    3.56   2.86 - 4.43   42%   0.00001   7
  *\<25% adj. Chemo*             4.51               3.21 - 6.35                   52%   0.00001   11   4.25   3.13 - 5.79   31%   0.00001   9
  *no adj. Chemo*                4.37               2.30 - 8.29                   57%   0.00001   4    3.1    2.00 - 4.78   0%    0.00001   2
  *no neoadj. Chemo*             3.48               2.96 - 4.10                   50%   0.00001   27   3.55   2.98 - 4.22   35%   0.00001   19

Legend: Legend: HR: Hazard Ratio; 95% CI: 95% confidence interval; CY = cytology; PCR = polymerase chain reaction

###### Subgroup analyses for disease free survival (DFS) and peritoneal recurrence free survival (PRFS) in FITC positive patients

                                   DFS    PRFS                                                                       
  -------------------------------- ------ -------------- ----- --------- ---- ------ -------------- ------ --------- ----
  **Total:**                       3.61   2.63 - 4.96    26%   0.00001   11   4.15   3.10 - 5.57    30%    0.00001   14
  **Multivariate:**                7.26   2.95 - 17.88   52%   0.00001   3    3.09   2.02 - 4.71    65%    0.00001   9
  **Detection Method:**                                                                                              
  *CY*                             4.37   2.22 - 8.60    38%   0.00001   4    4.94   3.27 - 7.47    15%    0.00001   8
  *PCR*                            3.42   2.32 - 5.03    28%   0.00001   7    4.06   2.86 - 5.76    0.36   0.00001   10
  **Stage of disease**                                                                                               
  *curative*                       4.21   2.59 - 6.86    43%   0.00001   7    5.07   3.28 - 7.82    0.55   0.00001   11
  *Advanced*                       9      3.60 - 22.54   0%    0.00001   2    3.21   1.85 - 5.58    56%    0.0001    5
  *not advanced*                   3.38   2.50 - 4.56    17%   0.0009    10   4.63   3.43 - 6.24    15%    0.00001   12
  **Date of publication**                                                                                            
  *up to and including 2005*       4.49   1.98 - 10.2    53%   0.0003    3    6.21   3.43 - 11.25   36%    0.00001   5
  *after 2005*                     3.41   2.40 - 4.85    21%   0.00001   8    3.4    2.54 - 4.55    9%     0.00001   9
  **Study population**                                                                                               
  *Asian*                          3.88   2.71 - 5.56    29%   0.00001   10   4.14   3.02 - 5.67    34%    0.00001   13
  *Western*                        2.66   1.48 - 4.80    NA    0.001     1    5.05   1.93 - 13.20   NA     0.0009    1
  **Size of study population**                                                                                       
  *\<median*                       4.82   2.73 - 8.52    21%   0.00001   5    5.28   3.14 - 8.88    31%    0.00001   7
  *\>median*                       3.08   2.16 - 4.38    18%   0.00001   6    3.58   2.56 - 5.00    25%    0.00001   7
  Risk of bias                                                                                                       
  *high*                           2.99   2.27 - 3.95    0%    0.00001   8    3.7    2.58 - 5.30    23%    0.00001   9
  *low*                            8.52   4.13 - 17.59   0.6   0.00001   3    5      3.00 - 8.35    42%    0.00001   5
  **Lavage fluid**                                                                                                   
  *\>150ml*                        3.5    2.44 - 5.03    0%    0.00001   5    5.22   3.42 - 7.98    17%    0.00001   7
  *\<150ml*                        4.13   2.31 - 7.40    52%   0.00001   6    3.41   2.29 - 5.07    36%    0.00001   7
  **Cytology positive patients**                                                                                     
  *\>median*                       3.77   2.44 - 5.83    26%   0.00001   5    3.27   2.06 - 5.17    42%    0.00001   5
  *\<=median*                      3.61   2.16 - 6.04    37%   0.00001   6    4.58   3.25 - 6.45    0%     0.00001   8
  **Chemotherapy**                                                                                                   
  *\>25% adj. Chemo*               2.29   1.25 - 4.21    NA    0.007     1    3      1.55 - 5.8     52%    0.001     2
  *\<25% adj. Chemo*               3.67   2.29 - 5.89    22%   0.00001   3    5.45   3.14 - 9.46    6%     0.00001   3
  *no adj. Chemo*                  3.26   2.12 - 5.00    0%    0.00001   2    5.05   1.93 - 13.2    NA     0.0009    1
  *no neoadj. Chemo*               3.99   2.62 - 6.06    47%   0.00001   8    4.67   3.28 - 6.66    0%     0.00001   6

Legend: HR: Hazard Ratio; 95% CI: 95% confidence interval; CY = cytology; PCR = polymerase chain reaction

Subgroup analyses {#s2_3}
-----------------

Subgroup analyses were performed to assess the impact of the detection method on the results. These analyses revealed a prognostic association of FITC detection by cytology with OS (3.03; 2.55 - 3.61; *n* = 35; I² = 78%) \[[@R10], [@R11], [@R13], [@R15]-[@R19], [@R21], [@R22], [@R24], [@R25], [@R28], [@R30], [@R33], [@R34], [@R38]-[@R41], [@R43], [@R44], [@R46], [@R47], [@R49]-[@R52], [@R57], [@R60], [@R61], [@R63], [@R65], [@R66], [@R69]\]. Despite a lower number of studies we observed a more pronounced prognostic value for pooled analyses of studies using RT-PCR (3.64; 2.93 - 4.53; *n* = 19; I² = 49%) \[[@R12], [@R20], [@R23], [@R26], [@R35], [@R38], [@R42], [@R45], [@R48], [@R53], [@R55]-[@R57], [@R59], [@R62], [@R64], [@R65], [@R67], [@R68]\]. This difference reached statistical significance in the test of interaction for the subgroup of patients who underwent potentially curative resection (*p* = 0.012). The kind of detection method had no impact on the prognostic value with respect to DFS and PRFS (Table [3](#T3){ref-type="table"}, Table [4](#T4){ref-type="table"}).

We next evaluated the prognostic value of FITC in patients with advanced stages as compared to the entire patient cohort. Only one study reported outcome selectively for patients with early stage of disease (without lymph node metastases) \[[@R51]\]. There was a significant association of FITC detection with OS in patients with advanced disease as well as the entire cohort. However, in particular for patients who underwent a potentially curative resection, the magnitude of effect was lower in case of advanced disease (2.52; 2.10 - 3.02; *n* = 12; I² = 24%)\[[@R16], [@R18], [@R25], [@R27], [@R30], [@R36], [@R47], [@R51], [@R59], [@R60], [@R65], [@R66]\] than for studies including the entire population (3.23; 2.98 - 3.50; *n* = 27; I² = 41%)\[[@R10]-[@R13], [@R17], [@R19], [@R22], [@R24], [@R31]-[@R35], [@R41], [@R45], [@R46], [@R48], [@R49], [@R51], [@R56], [@R59], [@R62], [@R65], [@R68], [@R69]\] (*p* = 0.014; test of interaction). The increased prognostic value of FITC detection in patients with less advanced disease was confirmed for PRFS (*p* = 0.008, test of interaction). There was not enough data for a pooled analysis of advanced disease for DFS (*n* = 2).

Previous studies suggested genetic differences between gastric cancers dependent on geographic location \[[@R74]-[@R76]\]. We therefore evaluated the prognostic value of FITC detection separately for these cohorts. These analyses showed a significant association between FITC detection and OS for Asian population (3.31; 2.77 - 3.95; *n* = 38; I² = 78%) \[[@R11]-[@R13], [@R16], [@R18], [@R20]-[@R22], [@R24], [@R26], [@R30]-[@R35], [@R38], [@R40], [@R41], [@R43], [@R45], [@R46], [@R48], [@R52], [@R55]-[@R57], [@R60]-[@R68]\] as well as Western population (3.17; 2.50 - 4.01; *n* = 13; I² = 48%) \[[@R10], [@R15], [@R17], [@R19], [@R28], [@R39], [@R44], [@R47], [@R49]-[@R51], [@R59], [@R69]\]. Significant associations for both cohorts were also present for patients who underwent a curative resection as well as the outcomes DFS and PRFS with no significant difference between both population as indicated by the tests of interaction.

Systemic chemotherapy has become common practice in the curative therapy of advanced gastric cancer \[[@R1], [@R77], [@R78]\], though the optimal regimen is still subject to intensive research \[[@R77]\]. Previous studies showed that 60-90% of FITC positive patients can be converted to FITC negative by neoadjuvant chemotherapy and thus improve survival \[[@R79], [@R80]\]. We therefore evaluated the prognostic value of FITC depending on the administration of neoadjuvant and adjuvant chemotherapy, respectively. These analyses revealed a strong association of FITC detection and OS, DFS and PRFS independent of the administration of neoadjuvant or adjuvant chemotherapy.

To exclude that the observed results were primarily caused by studies with low methodological quality, further analyses were stratified for the risk of bias. While studies with low (3.96; 2.92 - 5.38; *n* = 12; I² = 63%)\[[@R11], [@R28], [@R38], [@R39], [@R47], [@R48], [@R51], [@R55], [@R65]\] and high risk of bias (3.08; 2.62 - 3.62; *n* = 39; I² = 74%)\[[@R10], [@R13], [@R15]-[@R24], [@R26], [@R30]-[@R34], [@R40], [@R41], [@R43]-[@R46], [@R49], [@R50], [@R52], [@R56], [@R57], [@R59]-[@R64], [@R66]-[@R69]\] showed a significant prognostic value for FITC detection on OS, the effect was more pronounced in studies with low risk of bias (*p* = 0.15; test of interaction). The enhanced prognostic value reported in studies with a low risk of bias supports the validity of the finding that FITC detection represents a strong prognostic marker in gastric cancer.

DISCUSSION {#s3}
==========

This systematic review and meta-analysis shows a marked association of FITC with overall survival, disease free survival and peritoneal recurrence free survival of patients with gastric cancer scheduled for curative therapy.

Although the first studies on detection of FITC in gastric cancer patients have been published over 60 years ago \[[@R81]\], the role of FITC detection in the management of patients with gastric cancer has remained highly controversial. This may in part be explained by different study designs and insufficient statistical power of individual studies, in particular for subpopulations of patients with different extent of disease. In line with this, current gastric cancer treatment guidelines do not provide uniform recommendations on the use of peritoneal lavage. Although the majority of guidelines classify FITC detection as metastatic (M1) disease, these recommendations are based on single or a few individual studies, are limited to peritoneal lavage cytology and do not provide any standardization with respect to the sampling time and sampling/detection methodology (i.e. amount of lavage fluid, kind of staining). While the NCCN guidelines recommend a staging laparoscopy with peritoneal washings for cytology for stage IB and higher, the European ESMO, ESSO, ESTRO guidelines are less stringent and recommend a staging laparoscopy with or without peritoneal washings for malignant cells in these patients \[[@R1], [@R2]\]. Furthermore, there is no consensus regarding the consequences of a positive peritoneal cytology on patients' clinical management. In the NCCN guidelines a positive peritoneal cytology is considered a criterion of unresectability for cure. The European guidelines do not comment on the consequences for surgical resection and the German guidelines state no relevance on patients' further management \[[@R1], [@R2], [@R14]\]. As in these guidelines positive peritoneal cytology is classified as M1 disease and palliative treatment is recommended in M1 patients, there is urgent need to clarify which patients at what timepoint should undergo peritoneal lavage sampling by what methodology \[[@R26], [@R67], [@R73]\].

The results of the present meta-analysis confirm FITC as poor prognostic marker in patients with gastric cancer. Importantly, our results demonstrate the prognostic value of FITC detection to be dependent on the extent of disease. A more pronounced prognostic relevance is shown in patients with limited disease and a curative resection, respectively. Identification of strong prognostic markers might be useful in the management of gastric cancer patients in various ways. First, prognostic biomarkers might, moreover, serve as predictive biomarkers in patients considered for perioperative chemotherapy. Second, reliable prognostic information may be of particular help in decision-making for further treatment in elderly patients or patients with severe comorbidities who may be at increased risk for complications and poor outcome after multi-modal therapy. As total gastrectomy is associated with relevant morbidity and 90-day mortality, \[[@R82]\] a strong prognostic biomaker might be helpful to avoid surgery in high-risk patients with a poor prognosis. Third, it may be helpful in the management of young patients with excellent performance status who may be able to tolerate intensive therapy. Fourth, validation of FITC as strong prognostic biomarkers provide a valid scientific rationale for subsequent research to further characterize these cells on a molecular level. As targeted therapies are emerging for gastric cancer, \[[@R83]\] it is of particular interest, if molecular analysis of free intraperitoneal tumor cells might serve as a predictive biomarker for targeted agents in gastric cancer patients.

There is indeed increasing effort to identify patients with gastrointestinal malignancies and peritoneal metastases who benefit from intensified therapies such as HIPEC \[[@R84]-[@R86]\]. At present, these efforts mainly focus on patients with overt peritoneal metastases and showed promising results for colorectal cancer \[[@R87], [@R88]\]. The findings were much more modest for gastric cancer patients with overt peritoneal metastasis \[[@R89], [@R90]\] and may be explained by limitations to achieve complete cytoreduction \[[@R91]\]. These data suggest FITC positive gastric cancer without further distant metastasis as a promising subgroup of patients who might benefit from HIPEC. The first randomized controlled study to examine the benefit of extensive intraoperative peritoneal lavage followed by intraperitoneal chemotherapy in FITC positive gastric cancer showed promising results \[[@R92]\]. Further randomized controlled trials have already been initiated ([ClinicalTrials.gov](http://ClinicalTrials.gov); NCT01683864). The results may redefine the treatment of FITC positive gastric cancer.

The optimal method of FITC detection remains to be determined. As outlined current guidelines are restricted to conventional cytology without providing further information on the kind of staining. Our results indicate a prognostic value of FITC detection by cytology as well as molecular techniques. To date, only few studies directly compared cytology by Papanicolaou staining with molecular detection by PCR \[[@R23], [@R29], [@R38], [@R53], [@R55]-[@R57], [@R59], [@R65]\]. Detection methods using PCR offer a considerably higher detection sensitivity at a marginally lower specificity ([Appendix 3](#SD1){ref-type="supplementary-material"}). This meta-analysis demonstrates a similar prognostic value for both detection methods. The results of the above studies imply a potential superiority of FITC detection by PCR, that needs to be substantiated within prospective trials before valid recommendations can be made in guidelines.

The use of peritoneal lavage in patients undergoing multimodal therapy remains a further question to be answered. While metabolic imaging has been proposed as a strategy for early response assessment in patients with cancers of the esophagogastric junction and stomach \[[@R93]-[@R95]\], peritoneal washings with detection of FITC may offer an additional or alternative approach. There is indeed evidence that clearance of positive peritoneal cytology by systemic chemotherapy is associated with improved outcome after surgical resection for gastric cancer \[[@R96], [@R97]\]. However, controlled clinical trials are required to clarify the benefit of surgical resection in patients who remain positive for FITC after chemotherapy.

One important question that needs answering is how to proceed with FITC positive patients with potentially curative gastric cancer. Considering the results of this meta-analysis we would like to propose a therapeutic algorithm (Figure [3](#F3){ref-type="fig"}). However, the feasibility and clinical utility of this algorithm needs to be tested in controlled clinical trials.

![Treatment algorithm for gastric cancer](oncotarget-06-35564-g003){#F3}

In conclusion, this meta-analysis reveals FITC detection as poor prognostic marker in gastric cancer patients scheduled for curative therapy. The prognostic value of FITC was noted across detection methods, administration of chemotherapy and geographic location, though a more pronounced effect was observed in patients with less advanced disease. These results support efforts to use FITC as a predictive biomarker and may contribute to the development of uniform international treatment guidelines with the ultimate aim to improve individualized therapy and outcomes of patients with gastric cancer.

MATERIALS AND METHODS {#s4}
=====================

This systematic review was performed according to the recommendations of the PRISMA statement \[[@R98]\].

Search strategy {#s4_1}
---------------

A systematic search of the following databases was performed in December 2014: Medline, Science Citation Index, Embase, CCMed, Publisher Database, ASCO abstracts. Additionally, clinical trial registries such as WHO International Clinical Trials Registry and [ClinicalTrials.gov](http://ClinicalTrials.gov) were searched. Search strategies included the Medical Subject Headings (MeSH) "Stomach Neoplasm"; "Peritoneal Lavage"; "Therapeutic Irrigation"; "Cytology" as well as the text terms "gastric cancer", "peritoneal", "washing", "lavage" and "cytology" in various combinations. In addition, we searched the reference lists of relevant articles and review articles. No time and language restrictions were applied to the initial search. The identified titles and abstracts were screened for eligibility by two independent reviewers (MP and MA). Full articles of potentially relevant studies were obtained for detailed evaluation.

Study inclusion and exlcusion criteria {#s4_2}
--------------------------------------

Studies were included based on predefined selection criteria. Studies were eligible for inclusion, if they included patients with histologically proven gastric cancer and investigated the association of FITC with at least one of the following time-to-event outcomes: Overall survival (OS: date of surgery to date of death of any cause); disease specific survival (DSS: date of surgery to date of death due to gastric cancer); disease free survival (DFS: date of surgery to date of recurrence or death of any cause, whichever comes first), recurrence free survival (RFS: date of surgery to date of recurrence) or peritoneal recurrence (PR: date of surgery to date of peritoneal recurrence). Peritoneal cytology may have included any standard staining technique (i.e. hematoxylin and eosin \[H&E\], Papanicolaou) performed on peritoneal fluid or peritoneal washings. Molecular detection methods may have included immunocytochemistry and any form of reverse-transcriptase polymerase chain reaction (\[RT\]-PCR). In contrast to DNA or protein markers, studies using peritoneal tumor mRNA markers were included, assuming a linear correlation between peritoneal tumor cell detection and extremely short-lived free mRNA molecules.

Exclusion criteria were met, if less than 50 peritoneal samples were analyzed, if the percentage of patients with peritoneal or distant metastasis was \> 30%, if they were not published in a peer-reviewed journal, if the above mentioned definitions of peritoneal cytology or molecular diagnostic were not met or if no hazard ratio could be calculated for at least one of the above mentioned time-to-event outcomes.

Data extraction {#s4_3}
---------------

The following data was extracted from every article: first author, year of publication, study type, enrolment period, sample size, patient age and sex, FITC detection rate, definition of positive peritoneal fluid/lavage, timing of FITC detection, detection protocol, target genes and antigens, chemotherapy (neoadjuvant and/or adjuvant, treatment regimen), duration of follow up, reported outcomes and the use of multivariate models. The data for each included article were extracted independently by two authors (MP and MA). Diverging results were resolved by discussion.

Assessment of study quality {#s4_4}
---------------------------

Study quality was evaluated using the modified risk of bias tool recommended by the Cochrane Collaboration as described before \[[@R99], [@R100]\].

Statistical analyses {#s4_5}
--------------------

The synchronized extraction results were pooled statistically as effect estimates in meta-analyses. Hazard ratios (HR) and their corresponding standard errors (SE) were extracted for the individual time-to-event outcome parameters of the included studies. In case the HR together with their associated SE or confidence intervals (CI) were not provided for a certain outcome, HRs were calculated using different statistical methods based on the clinical and statistical data reported in the primary studies \[[@R101], [@R102]\].

The extracted HR were pooled using the generic inverse variance method of the Review Manager Version 5.3 software (Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2014). To adjust for expected inter-study heterogeneity (study populations, treatments, detection assays, definitions of FITC positivity, duration of follow-up, etc.) a random effects analysis model was applied, which is more conservative when determining confidence intervals (CI) around the pooled HR \[[@R103]\]. I^2^ statistics was applied to assess the presence of statistical heterogeneity \[[@R104]\]. To explore reasons for statistical heterogeneity we performed sensitivity analyses, where the impact of single studies on the I^2^ value is tested as well as "a priori" subgroup analyses \[[@R105]\]. The results of subgroup analyses were compared by tests of interaction \[[@R105]\]. To avoid double patient evaluation among studies that evaluated multiple detection assays and/or target genes, these parameters were combined where possible to keep a maximum of information. Otherwise, cytokeratins were prioritized over alternative tumor cell markers and immunohistochemistry over RT-PCR assays. Sensitivity analyses (by choosing the alternative study arm) were performed to assess the statistical impact of such prioritization. Publication bias was assessed using funnel plot analyses.

SUPPLEMENTARY MATERIAL {#s5}
======================
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